The Life Sciences team advised HiFiBiO Therapeutics on its two-year research collaboration and license agreement in acute myeloid leukemia (AML) with Kite, a Gilead Company (Nasdaq: GILD). Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies.
Under the terms of the agreement, HiFiBiO will receive an upfront payment and will be eligible for additional payments based on the achievement of certain research milestones. Kite will have an exclusive option to opt in on any targets discovered through the collaboration, for which HiFiBiO will receive an additional payment and will be eligible for additional development, regulatory and commercial milestone payments, as well as royalty payments.
HiFiBiO is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. Kite is engaged in the development of innovative cancer immunotherapies.For more details, read the press release and articles in Business Insider and Pharmaceutical Business Review.